Long‐term safety of vedolizumab for inflammatory bowel disease

BACKGROUND: Vedolizumab, a gut‐selective α(4)β(7) integrin antibody, is approved for moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). AIM: To report the final results from the vedolizumab GEMINI long‐term safety (LTS) study. METHODS: The phase 3, open‐label GEMINI...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Aliment Pharmacol Ther
मुख्य लेखकों: Loftus, Edward V., Feagan, Brian G., Panaccione, Remo, Colombel, Jean‐Frédéric, Sandborn, William J., Sands, Bruce E., Danese, Silvio, D’Haens, Geert, Rubin, David T., Shafran, Ira, Parfionovas, Andrejus, Rogers, Raquel, Lirio, Richard A., Vermeire, Séverine
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley and Sons Inc. 2020
विषय:
Efficacy and Safety of Biologics for Crohn's Disease
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540482/
https://ncbi.nlm.nih.gov/pubmed/32876349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.16060
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन